Seeking shorter, more effective, and economically viable treatment option for drug-resistant tuberculosis (DR-TB), a group of doctors and patients have sought urgent government intervention to roll out the BPaL regimen, comprising only three drugs – Bedaquiline, Pretomanid, and Linezolid.
(For top health news of the day, subscribe to our newsletter Health Matters)
The regimen, with a treatment duration of just 26 weeks, stands in stark contrast to the existing conventional treatment for DR-TB, which can require patients to take over 4,000 to 5,000 tablets over 18 to 21 months.
